Hims & Hers reports surprise loss in Q1, shares dive after hours

Hims & Hers reported a Q1 2026 net loss of $92.1 million, or $0.40 per share, missing the $0.01 EPS consensus as revenue came in at $608.1 million versus $616.5 million expected. U.S. revenue fell 8% year over year to $529.9 million, though total revenue still rose 4% and the company raised full-year 2026 revenue guidance to $2.8 billion-$3.0 billion from $2.7 billion-$2.9 billion. Shares fell nearly 10% after hours after the earnings miss and regulatory/legal pressure around its GLP-1 strategy.

Analysis

HIMS is now in the awkward middle of a monetization reset: the company is effectively swapping a high-margin, regulator-sensitive self-pay GLP-1 offering for a lower-risk but lower-take-rate branded distribution model. In the near term that should compress gross margin and raise customer acquisition payback periods, even if revenue growth re-accelerates; the market is likely underestimating how much of the new guidance depends on mix rather than true operating leverage. The key second-order effect is that this transition makes HIMS more of a volume-and-retention story than a pricing story, which tends to lower terminal multiples for consumer-health platforms.

For NVO, the partnership is strategically valuable because it turns a legal/regulatory fight into a distribution wedge: it reduces the chance of a prolonged channel conflict while expanding access to a digitally native customer base that is hard for traditional pharma to reach efficiently. That said, the upside for NVO is more about share-of-wallet and brand normalization than immediate earnings step-up; the market should treat this as a long-duration customer acquisition channel, not a near-term EPS catalyst. If the regulatory environment tightens further, the durable winner is likely the incumbent with manufacturing scale and compliance headroom, not the intermediary.

The more interesting trade is that the stock reaction in HIMS may still be too shallow if investors are pricing the raised revenue guide as evidence of durable demand rather than a temporary offset to margin deterioration. Over the next 1-3 quarters, the risk is that management leans harder on brand expansion and subscription growth while per-subscriber economics worsen, setting up a guidance-revision cycle if churn or reimbursement friction rises. Conversely, the contrarian bull case is that the company can use the broader assortment to improve retention enough to offset lower unit economics, but that requires proof in cohort data, not headline revenue.

Catalyst timing matters: HIMS can stabilize in days if management reframes the pivot as a regulated-scale advantage, but the fundamental verdict will come over 1-2 quarters as the market sees whether American-region weakness spreads or normalizes. The key tell is whether subscriber growth is accelerating faster than ARPU deterioration; if not, this is a multiple-compression story disguised as growth guidance.

Key Decisions for Investors

• Short HIMS on a 2-6 week horizon into any post-earnings relief bounce; use a tight stop above the pre-earnings gap fill. Risk/reward favors downside if the market starts marking down gross margin rather than topline growth.
• Pair trade: long NVO / short HIMS for 1-3 months. This captures the winner of regulatory de-risking and manufacturing scale versus the intermediary absorbing mix pressure and execution risk.
• Buy HIMS downside via put spreads 1-2 quarters out rather than outright shorts if borrow is tight. Best setup is a modest out-of-the-money spread to monetize a guidance-reset or margin disappointment.
• For longer-term accounts, trim any HIMS long exposure until management proves cohort retention and contribution margin resilience. The guide raise is not enough to justify re-rating without evidence that the new mix can scale profitably.
• Watch NVO on pullbacks for a tactical long; the partnership reduces headline legal overhang, and any future compliance tightening should favor the incumbent. Use 3-6 month horizon, but size modestly because the EPS impact is likely slower than sentiment improvement.